Therapeutic Application of Genome Editing Technologies in Viral Diseases.

Int J Mol Sci · 2022 · PMC9140762 · PMID 35628210

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

[ 116 ] developed an AAV vector to edit the HBV genome in liver-humanized FRG mice chronically infected with HBV through the CRISPR/Cas9 system and found that the HBV-specific AAV-Cas9 therapy significantly improved the human hepatocytes survival and showed a trend toward decreasing the amount of total liver HBV DNA and cccDNA.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.